BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 32221847)

  • 1. Nose-to-brain delivery: exploring newer domains for glioblastoma multiforme management.
    Upadhaya PG; Pulakkat S; Patravale VB
    Drug Deliv Transl Res; 2020 Aug; 10(4):1044-1056. PubMed ID: 32221847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials.
    Bruinsmann FA; Richter Vaz G; de Cristo Soares Alves A; Aguirre T; Raffin Pohlmann A; Stanisçuaski Guterres S; Sonvico F
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31779126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nose-to-brain delivery of antiglioblastoma drugs embedded into lipid nanocarrier systems: status quo and outlook.
    Sabir F; Ismail R; Csoka I
    Drug Discov Today; 2020 Jan; 25(1):185-194. PubMed ID: 31629966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nose-to-brain drug delivery for the treatment of glioblastoma multiforme: nanotechnological interventions.
    Kumar N; Khurana B; Arora D
    Pharm Dev Technol; 2023 Dec; 28(10):1032-1047. PubMed ID: 37975846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticle-Based Combinational Strategies for Overcoming the Blood-Brain Barrier and Blood-Tumor Barrier.
    Lim SH; Yee GT; Khang D
    Int J Nanomedicine; 2024; 19():2529-2552. PubMed ID: 38505170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nose to brain transport pathways an overview: potential of nanostructured lipid carriers in nose to brain targeting.
    Selvaraj K; Gowthamarajan K; Karri VVSR
    Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):2088-2095. PubMed ID: 29282995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
    van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
    Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic modulation of nasal epithelium augments neural stem cell targeting of glioblastoma.
    Spencer D; Yu D; Morshed RA; Li G; Pituch KC; Gao DX; Bertolino N; Procissi D; Lesniak MS; Balyasnikova IV
    Theranostics; 2019; 9(7):2071-2083. PubMed ID: 31037157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-Based Nanocarriers in the Treatment of Glioblastoma Multiforme (GBM): Challenges and Opportunities.
    Gupta T; Sahoo RK; Singh H; Katke S; Chaurasiya A; Gupta U
    AAPS PharmSciTech; 2023 Apr; 24(4):102. PubMed ID: 37041350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
    Karim R; Palazzo C; Evrard B; Piel G
    J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview.
    Djupesland PG; Messina JC; Mahmoud RA
    Ther Deliv; 2014 Jun; 5(6):709-33. PubMed ID: 25090283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breaching barriers in glioblastoma. Part II: Targeted drug delivery and lipid nanoparticles.
    Miranda A; Blanco-Prieto MJ; Sousa J; Pais A; Vitorino C
    Int J Pharm; 2017 Oct; 531(1):389-410. PubMed ID: 28801108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harnessing nanomedicine for therapeutic intervention in glioblastoma.
    Gutkin A; Cohen ZR; Peer D
    Expert Opin Drug Deliv; 2016 Nov; 13(11):1573-1582. PubMed ID: 27292970
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Gallego L; Ceña V
    Expert Opin Drug Deliv; 2020 Nov; 17(11):1541-1554. PubMed ID: 32791861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vesicular systems employing natural substances as promising drug candidates for MMP inhibition in glioblastoma: A nanotechnological approach.
    Agarwal S; Muniyandi P; Maekawa T; Kumar DS
    Int J Pharm; 2018 Nov; 551(1-2):339-361. PubMed ID: 30236647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug delivery approaches for the treatment of glioblastoma multiforme.
    Fakhoury M
    Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1365-73. PubMed ID: 26046399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Advances on Glioblastoma Multiforme and Nano-drug Carriers: A Review.
    Liao W; Fan S; Zheng Y; Liao S; Xiong Y; Li Y; Liu J
    Curr Med Chem; 2019; 26(31):5862-5874. PubMed ID: 29768997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug delivery systems from nose to brain.
    Misra A; Kher G
    Curr Pharm Biotechnol; 2012 Sep; 13(12):2355-79. PubMed ID: 23016642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal drug delivery for brain targeting.
    Vyas TK; Shahiwala A; Marathe S; Misra A
    Curr Drug Deliv; 2005 Apr; 2(2):165-75. PubMed ID: 16305417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.